Phico Therapeutics Ltd

Phico Therapeutics successfully raises £1m to develop products in their antibiotic platform technology, SASPjectTM, which is combats the problem of antibiotic resistance and bacterial toxin release when treating patients infected with E. Coli.

Wellcome Trust funded biotech Phico Therapeutics has attracted to their Board, Dr Anthony F. Martin, an experienced Non-Exec with solid track record of guiding early stage companies through to market.